Assessment of interlaboratory performance in the provision of perhexiline therapeutic drug monitoring services in Australia.
Perhexiline is a prophylactic antianginal agent particularly useful in patients whose angina is poorly controlled or refractory to conventional drug regimens. Although perhexiline can cause serious hepatic and neurological toxicity, maintaining trough plasma concentrations between 0.15-0.60 mg/L minimizes the risk of toxicity while providing relief of angina symptoms in a majority of patients. All pathology laboratories are required to participate in interlaboratory proficiency testing (PT) programs. The authors therefore initiated a monthly PT program to assess the performance of Australian laboratories measuring perhexiline (n = 8). PT specimens included perhexiline-spiked drug-free human plasma and pooled plasma from patients administered perhexiline. The performance of 8 Australian laboratories participating in the program was examined over a 30-month period. The mean relative standard deviation of the group was 18.2%. All centers performed well with respect to accuracy, achieving mean percentage bias within +/-8% of target perhexiline concentrations. The usefulness of the PT program was highlighted by the identification of two laboratories with an unacceptable degree of variability (up to 30% of results varied more than +/-55% from the target concentration), and the identification of potential analytical problems with the use of perhexiline metabolite concentrations for determining patients' hydroxylator status. Continued and improved use of PT by pathology laboratories is essential to ensuring the safe and effective clinical use of perhexiline.
Sallustio
B C
BC
Department of Clinical Pharmacology, The Queen Elizabeth Hospital, Woodville, South Australia.
Morris
R G
RG
D000787:Angina Pectoris / Q000188:drug therapy; D001315:Australia; D002317:Cardiovascular Agents / Q000097:blood* / Q000592:standards; D002849:Chromatography, Gas / Q000592:standards; D002851:Chromatography, High Pressure Liquid / Q000592:standards; D016903:Drug Monitoring / Q000379:methods* / Q000592:standards; D006801:Humans; D007753:Laboratories / Q000592:standards*; D010480:Perhexiline / Q000097:blood* / Q000592:standards; D011786:Quality Control; D015203:Reproducibility of Results
D002317:Cardiovascular Agents; D010480:Perhexiline